You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMeprobamate
Accession NumberDB00371  (APRD01095)
TypeSmall Molecule
GroupsApproved, Illicit
DescriptionA carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of anxiety disorders, and also for the short-term management of insomnia but has largely been superseded by the benzodiazepines. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) Meprobamate is a controlled substance in the U.S.
Structure
Thumb
Synonyms
Equanil
Meprobamat
Meprobamato
Meprobamatum
Meprobamic acid
Miltown
External Identifiers
  • DEA No. 2820
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Equanil Tablets 400mgTablet400 mgOralWyeth Ayerst Canada Inc.1994-12-312000-03-07Canada
Meditran 400mgTablet400 mgOralMedic Laboratory LtÉe1959-12-311996-09-09Canada
Meprobamate Tab 400mgTablet400 mgOralPro Doc Limitee1959-12-312001-10-15Canada
Meprobamate Tab 400mgTablet400 mgOralDuchesnay Inc1978-12-312001-10-15Canada
Novo-mepro 200mgTablet200 mgOralNovopharm Limited1967-12-312005-08-10Canada
Novo-mepro 400mgTablet400 mgOralNovopharm Limited1967-12-312005-08-10Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Meprobamate Tab 400mgTablet400 mgOralApotex Inc1975-12-312001-10-09Canada
MeprobamateTablet400 mg/1OralTaro Pharmaceutical Industries Ltd.2011-05-23Not applicableUs
MeprobamateTablet400 mg/1OralWatson Laboratories, Inc.1973-05-03Not applicableUs
MeprobamateTablet400 mg/1OralHeritage Pharmaceuticals Inc.2009-05-01Not applicableUs
MeprobamateTablet400 mg/1OralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
MeprobamateTablet200 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2011-05-23Not applicableUs
MeprobamateTablet200 mg/1OralDr.Reddy's Laboratories Limited2008-01-03Not applicableUs
MeprobamateTablet200 mg/1OralWatson Laboratories, Inc.1973-04-23Not applicableUs
MeprobamateTablet400 mg/1OralTaro Pharmaceuticals U.S.A., Inc.2011-05-23Not applicableUs
MeprobamateTablet400 mg/1OralDr.Reddy's Laboratories Limited2008-01-03Not applicableUs
MeprobamateTablet200 mg/1OralAlembic Pharmaceuticals Limited2013-07-23Not applicableUs
MeprobamateTablet200 mg/1OralAvera Mc Kennan Hospital2015-11-03Not applicableUs
MeprobamateTablet200 mg/1OralTaro Pharmaceutical Industries Ltd.2011-05-23Not applicableUs
MeprobamateTablet200 mg/1OralAlembic Pharmaceuticals Inc.2015-12-01Not applicableUs
MeprobamateTablet400 mg/1OralAlembic Pharmaceuticals Limited2013-07-23Not applicableUs
MeprobamateTablet200 mg/1OralHeritage Pharmaceuticals Inc.2009-05-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EquanilWyeth
MeprospanNot Available
MiltownWallace Laboratories
Brand mixtures
NameLabellerIngredients
282 Mep TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Equagesic TabletsWyeth Ayerst Canada Inc.
SaltsNot Available
Categories
UNII9I7LNY769Q
CAS number57-53-4
WeightAverage: 218.2502
Monoisotopic: 218.126657074
Chemical FormulaC9H18N2O4
InChI KeyNPPQSCRMBWNHMW-UHFFFAOYSA-N
InChI
InChI=1S/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)
IUPAC Name
2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
SMILES
CCCC(C)(COC(N)=O)COC(N)=O
Pharmacology
IndicationFor the management of anxiety disorders or for the short-term relief of the symptoms of anxiety.
Structured Indications
PharmacodynamicsMeprobamate is an anxiolytic drug. It was the best selling minor tranquilizer for a time but has largely been replaced by benzodiazepines. Meprobamate has most of the pharmacological effects and dangers of the barbiturates (though it was marketed as being safer). However, it is less sedating at effective doses. It is reported to have some anticonvulsant properties against absence seizures, but can exacerbate generalized tonic-clonic seizures. It has also been used as a hypnotic (sleeping pill). However, its is currently only licensed as an anxiolytic and it is a third or fourth-order choice.
Mechanism of actionMeprobamate's mechanism of action is not known. It has been shown in animal studies to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Meprobamate binds to GABAA receptors which interrupt neuronal communication in the reticular formation and spinal cord, causing sedation and altered perception of pain.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
agonist
HumanP14867 details
Gamma-aminobutyric acid receptor subunit alpha-2Proteinyes
agonist
HumanP47869 details
Gamma-aminobutyric acid receptor subunit alpha-3Proteinyes
agonist
HumanP34903 details
Gamma-aminobutyric acid receptor subunit alpha-4Proteinyes
agonist
HumanP48169 details
Gamma-aminobutyric acid receptor subunit alpha-5Proteinyes
agonist
HumanP31644 details
Gamma-aminobutyric acid receptor subunit alpha-6Proteinyes
agonist
HumanQ16445 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifePlasma half-life is about 10 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include coma, drowsiness, loss of muscle control, severely impaired breathing, shock, sluggishness, and unresponsiveness. Death has been reported with ingestion of as little as 12 g meprobamate and survival with as much as 40 g.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Capecitabine Metabolism PathwayDrug metabolismSMP00607
Capecitabine Action PathwayDrug actionSMP00469
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Meprobamate can be decreased when combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Meprobamate.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aceprometazine.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Meprobamate.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Meprobamate.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Meprobamate.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Agomelatine.Approved, Investigational
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Meprobamate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Meprobamate.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Alprazolam.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Meprobamate.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Meprobamate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Amperozide.Experimental
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Meprobamate.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Meprobamate can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Meprobamate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Asenapine.Approved
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Meprobamate.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Meprobamate.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Meprobamate.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azaperone.Vet Approved
AzelastineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Meprobamate is combined with Benzyl alcohol.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Meprobamate.Approved, Vet Approved
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Meprobamate.Approved
BortezomibThe metabolism of Meprobamate can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Meprobamate.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Meprobamate.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Bromazepam.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Meprobamate.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Meprobamate.Approved, Investigational
BuprenorphineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Buspirone.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Meprobamate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Meprobamate.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Meprobamate.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Meprobamate.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Meprobamate.Approved
CarbamazepineThe metabolism of Meprobamate can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carfentanil.Illicit, Vet Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Meprobamate.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Meprobamate.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Meprobamate.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Meprobamate can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlordiazepoxide.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorphenamine.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Meprobamate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Meprobamate can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Meprobamate.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Meprobamate.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Meprobamate.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Meprobamate.Approved
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Meprobamate.Approved
ClemastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clidinium.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Meprobamate.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with clomethiazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Meprobamate.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clonazepam.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Meprobamate.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Meprobamate.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Meprobamate can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Meprobamate.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Meprobamate.Approved
CocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Meprobamate.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Meprobamate.Approved
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Meprobamate.Approved
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Meprobamate.Approved
CyclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.Approved
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Meprobamate.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Meprobamate can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Meprobamate.Approved
DabrafenibThe serum concentration of Meprobamate can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Meprobamate.Approved
DantroleneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dantrolene.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Meprobamate.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Meprobamate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dapoxetine.Investigational
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Meprobamate.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Meprobamate.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Meprobamate.Approved
DelavirdineThe metabolism of Meprobamate can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Meprobamate.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dezocine.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Meprobamate.Approved, Illicit, Vet Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Meprobamate.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Meprobamate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Meprobamate.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dihydromorphine.Experimental, Illicit
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Meprobamate.Illicit
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Meprobamate.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Meprobamate.Approved
DisulfiramThe metabolism of Meprobamate can be decreased when combined with Disulfiram.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Meprobamate.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Meprobamate.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Meprobamate.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Meprobamate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Meprobamate is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Meprobamate.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Meprobamate.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Meprobamate.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Entacapone.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Meprobamate.Approved, Investigational
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Meprobamate.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Meprobamate.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Meprobamate can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Meprobamate can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Estazolam.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Meprobamate.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Meprobamate.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Meprobamate.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Eszopiclone.Approved
EthanolMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Meprobamate.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Meprobamate.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Meprobamate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Meprobamate.Approved
EtorphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Meprobamate can be decreased when combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Meprobamate.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Meprobamate.Approved
EzogabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Meprobamate.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Meprobamate.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Meprobamate.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flibanserin.Approved
FluconazoleThe metabolism of Meprobamate can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Meprobamate can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluphenazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluspirilene.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Meprobamate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Meprobamate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Meprobamate can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Meprobamate is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Meprobamate.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Meprobamate.Approved
GemfibrozilThe metabolism of Meprobamate can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Glutethimide.Approved, Illicit
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Meprobamate.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Meprobamate.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Meprobamate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Hexobarbital.Approved
HydrocodoneMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Meprobamate.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Meprobamate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Meprobamate.Approved
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Meprobamate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Iloperidone.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Meprobamate.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Meprobamate.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Meprobamate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Meprobamate.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Meprobamate.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Meprobamate.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Isoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Meprobamate can be decreased when combined with Isoniazid.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Meprobamate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Meprobamate.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ketobemidone.Approved
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Meprobamate.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Meprobamate.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Meprobamate.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Meprobamate.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Meprobamate.Approved
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Meprobamate.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Meprobamate.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Meprobamate.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levodopa.Approved
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Meprobamate.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Meprobamate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Meprobamate.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Meprobamate.Approved
LithiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lofentanil.Illicit
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Meprobamate.Approved
LopinavirThe metabolism of Meprobamate can be increased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Meprobamate.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Meprobamate.Approved
LoxapineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Loxapine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Meprobamate is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Meprobamate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Meprobamate can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Vet Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Meprobamate.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mepivacaine.Approved, Vet Approved
MesoridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Meprobamate.Approved
MethotrimeprazineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Meprobamate.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Meprobamate.Approved, Investigational
MetyrosineMeprobamate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Mianserin.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Meprobamate.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Meprobamate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Meprobamate.Approved
MirtazapineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Meprobamate.Approved, Investigational
MoclobemideThe metabolism of Meprobamate can be decreased when combined with Moclobemide.Approved
ModafinilThe metabolism of Meprobamate can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Molindone.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Meprobamate.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Meprobamate.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nalbuphine.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Meprobamate.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Meprobamate.Approved, Vet Approved
NefazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Meprobamate.Approved
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Meprobamate.Approved
NicotineThe metabolism of Meprobamate can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Meprobamate.Approved
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Meprobamate.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Meprobamate.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nitrous oxide.Approved, Vet Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Meprobamate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Nortriptyline.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Meprobamate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Olopatadine.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Meprobamate.Approved
OmeprazoleThe metabolism of Meprobamate can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Meprobamate is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Meprobamate can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Meprobamate is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Meprobamate.Approved
OxazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxymorphone.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Meprobamate.Approved, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paliperidone.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Meprobamate.Approved, Investigational
PantoprazoleThe metabolism of Meprobamate can be decreased when combined with Pantoprazole.Approved
ParaldehydeMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Meprobamate.Approved
PentazocineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Meprobamate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
PerazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pethidine.Approved
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Meprobamate.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Phenoxyethanol.Approved
PhenytoinThe metabolism of Meprobamate can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Piritramide.Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Meprobamate.Approved
PizotifenThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pizotifen.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Meprobamate.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Meprobamate.Approved
PramipexoleMeprobamate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pramocaine.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Meprobamate.Approved
PrazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam.Approved, Illicit
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Meprobamate.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Meprobamate.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Meprobamate.Approved, Vet Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Meprobamate.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Meprobamate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Propoxycaine.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Meprobamate.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Meprobamate.Approved
PSD502The risk or severity of adverse effects can be increased when Meprobamate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Meprobamate.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Meprobamate.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Meprobamate.Approved
RacloprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ramelteon.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Meprobamate.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Meprobamate.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Meprobamate.Approved
RifampicinThe metabolism of Meprobamate can be increased when combined with Rifampicin.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Meprobamate.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Meprobamate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Meprobamate.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Meprobamate.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Meprobamate.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Romifidine.Vet Approved
RopiniroleMeprobamate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Meprobamate.Approved
RotigotineMeprobamate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Meprobamate.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Meprobamate is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Meprobamate is combined with Sage 547.Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Meprobamate.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Meprobamate.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Secobarbital.Approved, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Meprobamate.Approved
SertindoleThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Meprobamate can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Meprobamate.Approved
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Meprobamate.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Meprobamate.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Meprobamate.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Meprobamate.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Meprobamate.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Meprobamate.Experimental
StiripentolThe metabolism of Meprobamate can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sulpiride.Approved
SuvorexantMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Meprobamate.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Meprobamate.Approved
TandospironeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tasimelteon.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Meprobamate.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Meprobamate.Approved
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Meprobamate.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Meprobamate.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Meprobamate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tetrodotoxin.Investigational
ThalidomideMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thioridazine.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Meprobamate.Approved
TiclopidineThe metabolism of Meprobamate can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tiletamine.Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Meprobamate.Approved
TizanidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tolcapone.Approved, Withdrawn
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Meprobamate.Approved
TopiramateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Meprobamate.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Meprobamate.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Meprobamate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Meprobamate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Meprobamate is combined with Uc1010.Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Meprobamate.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Meprobamate.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Meprobamate.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Meprobamate.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Meprobamate.Approved
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Meprobamate.Approved
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Meprobamate.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vigabatrin.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Meprobamate.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Meprobamate.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Meprobamate.Approved
VoriconazoleThe metabolism of Meprobamate can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Meprobamate can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ziconotide.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Meprobamate.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Meprobamate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zolazepam.Vet Approved
ZolpidemMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Meprobamate is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN05BC51N05CX01N05BC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (52.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9534
Blood Brain Barrier+0.9864
Caco-2 permeable-0.5731
P-glycoprotein substrateNon-substrate0.5282
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9033
Renal organic cation transporterNon-inhibitor0.945
CYP450 2C9 substrateNon-substrate0.9108
CYP450 2D6 substrateNon-substrate0.8961
CYP450 3A4 substrateNon-substrate0.7032
CYP450 1A2 substrateNon-inhibitor0.8381
CYP450 2C9 inhibitorNon-inhibitor0.8799
CYP450 2D6 inhibitorNon-inhibitor0.8764
CYP450 2C19 inhibitorNon-inhibitor0.8754
CYP450 3A4 inhibitorNon-inhibitor0.8735
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8914
Ames testNon AMES toxic0.8706
CarcinogenicityNon-carcinogens0.7304
BiodegradationNot ready biodegradable0.965
Rat acute toxicity2.4075 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9943
hERG inhibition (predictor II)Non-inhibitor0.9322
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline llc
  • Medpointe pharmaceuticals medpointe healthcare inc
  • Wyeth ayerst laboratories
  • Ferndale laboratories inc
  • Alra laboratories inc
  • Teva pharmaceuticals usa inc
  • Alembic ltd
  • Barr laboratories inc
  • Elkins sinn div ah robins co inc
  • Heather drug co inc
  • Impax laboratories inc
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Ivc industries inc dba inverness medical nutritionals group
  • Lannett co inc
  • Lederle laboratories div american cyanamid co
  • Km lee laboratories inc
  • Mallard inc
  • Mk laboratories inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nexgen pharma inc
  • Parke davis div warner lambert co
  • L perrigo co
  • Pharmavite pharmaceuticals
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Scherer laboratories inc
  • Solvay pharmaceuticals
  • Stanlabs pharmaceutical co sub simpak corp
  • Tablicaps inc
  • Usl pharma inc
  • Valeant pharmaceuticals international
  • Vangard laboratories inc div midway medical co
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Halsey drug co inc
Packagers
Dosage forms
FormRouteStrength
TabletOral
TabletOral400 mg
TabletOral200 mg/1
TabletOral400 mg/1
TabletOral200 mg
Prices
Unit descriptionCostUnit
Mepron 750 mg/5ml Suspension5.41USD ml
Mepron 750 mg/5 ml suspension4.95USD ml
Meprobamate 200 mg tablet1.42USD tablet
Meprobamate 400 mg tablet0.84USD tablet
Meprozine 50-25 mg capsule0.78USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1336266 No1995-07-112012-07-11Canada
CA2152615 No2001-10-162013-12-23Canada
US4981874 No1992-08-152009-08-15Us
US6649659 No1997-01-102017-01-10Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point105 °CPhysProp
water solubility4700 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP0.70HANSCH,C ET AL. (1995)
logS-1.67ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility2.47 mg/mLALOGPS
logP1.06ALOGPS
logP0.93ChemAxon
logS-1.9ALOGPS
pKa (Strongest Acidic)15.17ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area104.64 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity53.04 m3·mol-1ChemAxon
Polarizability22.65 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as organooxygen compounds. These are organic compounds containing a bond between a carbon atom and an oxygen atom.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassNot Available
Sub ClassNot Available
Direct ParentOrganooxygen compounds
Alternative Parents
Substituents
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Rho JM, Donevan SD, Rogawski MA: Barbiturate-like actions of the propanediol dicarbamates felbamate and meprobamate. J Pharmacol Exp Ther. 1997 Mar;280(3):1383-91. [PubMed:9067327 ]
  2. Gonzalez LA, Gatch MB, Taylor CM, Bell-Horner CL, Forster MJ, Dillon GH: Carisoprodol-mediated modulation of GABAA receptors: in vitro and in vivo studies. J Pharmacol Exp Ther. 2009 May;329(2):827-37. doi: 10.1124/jpet.109.151142. Epub 2009 Feb 24. [PubMed:19244096 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23